Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04838873
Other study ID # SO1901-31004
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 24, 2019
Est. completion date December 30, 2020

Study information

Verified date April 2021
Source Cairo University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a prospective randomised controlled study of urinary bladder cancer patients presented to urology unit at National Cancer Institute; Cairo University.


Description:

The study will randomise 60 patients to one of two arms; laparoscopic-assisted radical cystectomy and open radical cystectomy. The focus of the study will be a comparison of both approaches on the patients' peri-operative outcome.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date December 30, 2020
Est. primary completion date July 1, 2019
Accepts healthy volunteers No
Gender All
Age group 30 Years to 80 Years
Eligibility Inclusion Criteria: - Patients with transitional cell carcinoma, squamous cell carcinoma and urinary bladder adenocarcinoma. - Patients fit for surgery (ECOG Performance Status 0,1). Exclusion Criteria: - Patients with medical comorbidities that preclude surgical management or minimally invasive techniques. - Patients with advanced hydronephrosis or renal failure. - Patients refusing surgery. - Patients with urinary bladder cancer invading bladder neck or prostatic urethra. - Patients with metastatic urinary bladder cancer. - Patients who received prior pelvic radiotherapy. - Patients refusing randomization and/or participation in the trial.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Open radical cystectomy
Standard open radical cystectomy and urinary diversion
Laparoscopic-assisted radical cystectomy
Laparoscopic-assisted radical cystectomy and extracorporeal urinary diversion

Locations

Country Name City State
Egypt National Cancer Institute Cairo

Sponsors (1)

Lead Sponsor Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Operative time OR time as measured in minutes, divided into time required to perform the cystectomy, lymph node dissection, and urinary diversion. During surgery
Primary Blood loss EBL as measured in millilitres, including the effluent from the suction canister as well as estimates of the gauze swabs. During surgery
Primary Length of hospital stay LOS as measured in days Immediate post-operative period.
Primary Time to oral intake Measured in days Immediate post-operative period
Primary Conversion rate Rate of conversion from laparoscopy to open surgery During surgery
Primary Re-admission rate. Re-hospitalization requirement. Intra-operative to sixth months.
Primary Opioid requirements. Requirement, dose and duration of narcotic analgesia. During surgery through first post-operative week.
Primary Visceral injury Any organ injury encountered during the operation. During surgery
Primary Urine leak Leakage of urine from urinary enteric anastomosis Up to 4 weeks
Primary Wound dehiscence, infection. Wound gaping, evisceration or infection. Up to 4 weeks
Primary Enteric fistula Leakage of intestinal contents due to failure of entero-enteric anastomosis Up to 4 weeks
Primary Sepsis Infection triggering a systematic immune response Up to 4 weeks
Primary Venous thromboembolism DVT or pulmonary embolism Up to 2 months
Secondary pT stage Pathologic tumor stage (Stage 1, stage 2, stage 3 or stage 4) Within 10 days post surgery.
Secondary Lymph node retrieval Number of lymph nodes retrieved by open versus laparoscopic approaches. Within 10 days post surgery.
Secondary pN stage Lymph node metastasis (positive or negative), and number of positive nodes if present. Within 10 days post surgery.
Secondary Surgical margins Positive margins or negative margins. Location of positive margins (Urethral, ureteric) Within 10 days post surgery
Secondary Histological grade Low grade, intermediate grade or high grade Within 10 days post surgery
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06034015 - A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers Phase 1
Recruiting NCT04235764 - En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
Completed NCT02371447 - VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer Phase 1/Phase 2
Recruiting NCT04081246 - Transurethral Modified En Bloc Resection For Large Bladder Tumours. N/A
Recruiting NCT06059547 - Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer Phase 2
Terminated NCT04779489 - Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer N/A
Not yet recruiting NCT04493489 - Propranolol Adjuvant Treatment of Bladder Cancer Phase 2
Completed NCT03520231 - Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases Phase 2
Recruiting NCT04537221 - Nordic Cystectomy Study III - Transfusion
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Completed NCT01955408 - Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment N/A
Completed NCT04487457 - Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Recruiting NCT05562791 - A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer Phase 1
Completed NCT00199849 - NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine Phase 1
Completed NCT02781428 - To Detect the Sensitivity of the UroMark Assay
Recruiting NCT04738630 - Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer Phase 2
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2
Active, not recruiting NCT03978624 - Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer Phase 2
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A